Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Sponsor
UNC Lineberger Comprehensive Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT01137643
Collaborator
National Cancer Institute (NCI) (NIH)
15,000
Enrollment
1
Location
372
Duration (Months)
40.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.

PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.

Detailed Description

OBJECTIVES:
  • Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies.

  • Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies.

  • Maintain responsible and appropriate policies and procedures that ensure good patient care and responsible conduct of research.

  • Address medical and legal issues, and protect participant and patient privacy and confidentiality.

  • Provide a responsible and uniform mechanism for the integrated coordination of the hemato-pathologist and surgeon or hematology/oncology staff, researcher, and protocol office to obtain appropriate specimens for researchers.

  • Support young investigators to obtain pilot data for grant funding.

OUTLINE: Patients undergo tissue, blood, and body fluid collection during diagnostic or routine procedures for future correlative studies. Tissue samples may include, but are not limited to, lymph node or non-nodal biopsies, bone marrow biopsy and/or aspirate, blood and serum, and buccal swabs for germline DNA analysis.

Study Design

Study Type:
Observational
Anticipated Enrollment :
15000 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Tissue Procurement For Hematolymphoid Conditions
Study Start Date :
Jul 1, 2009
Anticipated Primary Completion Date :
Jul 1, 2040
Anticipated Study Completion Date :
Jul 1, 2040

Outcome Measures

Primary Outcome Measures

  1. Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies [30 years]

  2. Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens [30 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 120 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
DISEASE CHARACTERISTICS:
  • Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following:

  • Acute myeloid leukemia

  • Acute lymphoblastic leukemia

  • Chronic myelogenous leukemia

  • Chronic lymphoid leukemia

  • Non-Hodgkin lymphoma

  • Hodgkin lymphoma

  • Myelodysplastic syndromes

  • Myeloproliferative disorders

  • Multiple myeloma

  • Waldenstrom macroglobulinemia

  • Aplastic anemia

  • Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage

  • Patients who are being evaluated at the hematology/oncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital

PATIENT CHARACTERISTICS:
  • Not specified
PRIOR CONCURRENT THERAPY:
  • Not specified

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel HillChapel HillNorth CarolinaUnited States27599-7295

Sponsors and Collaborators

  • UNC Lineberger Comprehensive Cancer Center
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Paul Armistead, MD, UNC Lineberger Comprehensive Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01137643
Other Study ID Numbers:
  • LCCC 0824
  • P30CA016086
  • CDR0000674072
First Posted:
Jun 4, 2010
Last Update Posted:
Oct 15, 2021
Last Verified:
Oct 1, 2021
Keywords provided by UNC Lineberger Comprehensive Cancer Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 15, 2021